News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Emperra Appoints Christian Krey As New CEO To Market ESYSTA® Telediabetology System


2/11/2014 9:17:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Potsdam, Germany, February 11, 2014 / B3C newswire / - EMPERRA® GmbH E-Health Technologies, specializing in e-health technologies and telediabetology, today announced the appointment of Dr. Christian Krey as Managing Director and CEO. Dr. Krey has many years of experience in the field of diabetes mellitus and was previously employed as Business Unit Manager at a Johnson & Johnson subsidiary. Prior to that, Dr. Krey held various positions in the field of diabetes at Lilly, Berlin Chemie and A. Menarini Diagnostics. In the future, Dr. Mertens, who has held the position of Managing Director and CEO for the past three years, will be assuming the role of VP Business Development. Dr. Schildt continues to be the responsible Managing Director for the fields of Medicine and Technology.

With ESYSTA®, the company EMPERRA® GmbH E-Health Technologies has developed and launched the world's first GSM- and Web-based telemedical total management system for diabetes mellitus type 1 and 2 requiring insulin. The ESYSTA® portfolio is totally CE-certified according to the Medical Product Act (MPG) in hardware and software and thus approved for marketing and sales in the EU. Furthermore, data protection and IT security requirements are fulfilled by the ESYSTA® system. Parts of the ESYSTA® portfolio are already listed in the range of services of statutory health insurance (GKV) and thus approved for extensive prescription by physicians.

For the first time, ESYSTA® enables all data such as insulin dose, blood glucose readings and carbohydrate units are completely recorded. Via cell phone and with the assistance of a Web-based assessment platform, all relevant data are always available on computers, tablets and smart phones (Android®/iOS®) not only to patients/family members but also to physicians in private practice and clinics. ESYSTA® significantly improves diagnostics, therapy, patient guidance, patient compliance, self-empowerment and quality of life. The ESYSTA® product system additionally leads to a significant cost reduction for statutory health funds and reimbursers for the highly-prevalent, cost-intensive chronic illness, "diabetes mellitus".

With the patented ESYSTA® pen, for the first time worldwide, there is now an insulin pen that uses all insulins of major insulin suppliers and can thus be used for all patients without having to change the insulin therapy. The ESYSTA® insulin pen ensures that all insulin doses administered by patients are recorded, transmitted via wireless and documented in the ESYSTA® portal.

Dr. Klaus Stöckemann, Chairman of the Advisory Board of EMPERRA® GmbH and Managing Director of Peppermint Venture Partners explains: "With Dr. Krey, we are elated to have recruited an experienced manager for Emperra from the field of diabetes. At the same time, we also owe great gratitude to Dr. Mertens for his work over the past three years and are pleased that he will continue to be a part of the company in his new important role."

Dr. Christian Krey, Managing Director and CEO of EMPERRA® GmbH explains: “I am very happy to be at Emperra and to utilise my many years of experience in the field of diabetes, in order to position in the market and further develop the ESYSTA® system. This system is unique and will help improve the care for persons with diabetes. For the first time, it enables all stakeholders to be involved."

About EMPERRA® GmbH E-Health Technologies

EMPERRA® GmbH E-Health Technologies was founded in 2008 in Potsdam and is focusing on the development of new telediabetological systems such as ESYSTA® and further innovations that are in product development.

The company furthermore offers telemedical services and, in doing so, also acts as a management firm. An initial comprehensive pilot project providing to approx. 300 patients was contracted with a German Local Health Insurance Funds on the basis of Social Security Code (SGB) V, § 140 ff. and publicised throughout Europe. The initial interim assessment of this key project, involving more than 30 diabetologists, has already demonstrated a significant improvement in the patients' overall metabolic condition.

Contacts:
Dr. Christian Krey
CEO
EMPERRA® GmbH E-Health Technologies
Friedrich-Ebert-Straße 33
D-14469 Potsdam, Germany
c.krey@emperra.com
Dr. Klaus Stöckemann
Managing Director
Peppermint Venture Partners
ks@peppermint-vp.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES